KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities from Discontinued Operations: 2010-2024

Historic Liabilities from Discontinued Operations for TherapeuticsMD (TXMD) over the last 5 years, with Dec 2024 value amounting to $2.8 million.

  • TherapeuticsMD's Liabilities from Discontinued Operations fell 8.79% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 8.79%. This contributed to the annual value of $2.8 million for FY2024, which is 24.72% down from last year.
  • As of FY2024, TherapeuticsMD's Liabilities from Discontinued Operations stood at $2.8 million, which was down 24.72% from $3.7 million recorded in FY2023.
  • TherapeuticsMD's Liabilities from Discontinued Operations' 5-year high stood at $47.9 million during FY2021, with a 5-year trough of $2.8 million in FY2024.
  • For the 3-year period, TherapeuticsMD's Liabilities from Discontinued Operations averaged around $10.8 million, with its median value being $3.7 million (2023).
  • Data for TherapeuticsMD's Liabilities from Discontinued Operations shows a maximum YoY slumped of 85.70% (in 2023) over the last 5 years.
  • Over the past 4 years, TherapeuticsMD's Liabilities from Discontinued Operations (Yearly) stood at $47.9 million in 2021, then tumbled by 46.09% to $25.8 million in 2022, then plummeted by 85.70% to $3.7 million in 2023, then fell by 24.72% to $2.8 million in 2024.